RADNOR, Pa., Dec. 7, 2011 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that an interim analysis of results from more than 80 patients enrolled in its Phase 2 clinical trial with PMX-30063 defensin-mimetic antibiotic, indicate that all dosing arms in the study were both safe and effective in treating patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by S. aureus. This is the first ever patient clinical efficacy study conducted with this new defensin-mimetic antibiotic class. PolyMedix is continuing to enroll patients and expects to complete the full trial in the first half of 2012.
